Halozyme Therapeutics, Inc., and Skye Bioscience, Inc., announced a global collaboration and license agreement in December 2025 to explore the use of nimacimab co-formulated with Halozyme’s ENHANZE drug delivery technology for obesity. Under this non-exclusive agreement, Skye Bioscience will use ENHANZE to develop a subcutaneous formulation of nimacimab that allows for higher doses and larger injection volumes. The collaboration aims to support Skye’s evaluation of dose-ranging strategies and potential combinations with GLP-1 receptor agonists for obesity treatment.
Health Technology Insights: OsteoCentric Technologies Appoints Matthew Collier to Board of Directors
Dr. Helen Torley, President and Chief Executive Officer of Halozyme, said the partnership demonstrates the versatility of ENHANZE technology and its potential in the growing obesity market. She noted that the agreement strengthens Halozyme’s strategy to expand its reach across multiple therapeutic areas while driving sustainable royalty growth through innovative collaborations.
Health Technology Insights: Samsung Biologics Acquires Human Genome Sciences from GSK
Punit Dhillon, President and Chief Executive Officer of Skye Bioscience, explained that higher doses of nimacimab require an effective and practical method for subcutaneous delivery. Partnering with Halozyme provides a validated approach to test multiple dosing strategies and combination therapies, supporting the development of nimacimab as a viable treatment option for obesity.
As part of the agreement, Skye will make milestone payments tied to key development and commercialization milestones, while Halozyme will receive mid-single-digit royalties on net sales of nimacimab developed with ENHANZE for at least ten years. Skye plans to begin a Phase 2b clinical trial in mid-2026 to evaluate the subcutaneous formulation of nimacimab, including its combination with a GLP-1 receptor agonist. This collaboration underscores both companies’ commitment to advancing obesity treatments through innovative drug delivery solutions.
Health Technology Insights: SCIENTURE Launches FDA-Approved High-Strength REZENOPY
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
